ReportGem ReportGem EN

普通外文研报

Classys Inc: Risk Reward Update

发布日期: 2026-07-05研究机构: Morgan Stanley公司 / 股票: 214150.KQ报告页数: 9原文语言: 英语证据页码: 2

研报英文原文证据摘录

Classys Inc: Risk Reward Update

UpdateM

RiskRisk RewardReward– Classys- ClassysInc (214150.KQ)Inc (214150.KQ)

RF device sales are rising but HIFU device sales are a drag; EW

PRICE TARGET W55,000 EQUAL-WEIGHT THESIS

We derive our price target (base case) from a DCF model to best capture the company's ▪Exports accounted for 67% of total sales

sustainable growth potential over the longer term. We assume a 9.3% cost of equity (beta in 2025.

1.05, risk-free rate 3.0% and risk premium 6.0%) and 4.0% terminal growth and FCF growth. ▪In 2025, existing Ultraformer franchise

Reflecting strong growth outlooks for skin tightening device markets (8.5% growth seen (HIFU brand for exports) device unit exports

from 2021 to 2029), we believe our long-term growth assumption is justified. were flat, but the new RF device Volnewmer

exports grew c.60% YoY. W77,313

rate the shares EW relative to ourConsensus Price Target Distribution W55,000 W95,000.00 ▪We coverage. We believe medical beauty device MS PT

Source: Refinitiv, Morgan Stanley Research Mean Morgan Stanley Estimates makers need to launch new products every

three to four years to sustain good growth,

but note it is difficult to predict future

product launches or successes. Also, margin

RISK REWARD CHART will likely decrease due to the acquisition of

MedSystems (a distributor in Brazil) in

March 2026.

KRW

W98,000W98,000(+110.98%)W98,000(+110.98%)(+110.98%)

Consensus Rating Distribution

95% Overweight

5% Equal-weight

75000 0% Underweight

MS Rating

W55,000W55,000(+18.41%)W55,000(+18.41%)(+18.41%)

50000 W46,450W46,450W46,450 Source: Refinitiv, Morgan Stanley Research

25000 Risk Reward Themes

W31,000W31,000(-33.26%)W31,000(-33.26%)(-33.26%)

Contrarian: Negative

View descriptions of Risk Rewards Themes here

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器